Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NutraCea files for bankruptcy

This article was originally published in The Tan Sheet

Executive Summary

The stabilized rice brand nutrient research and technology company files for Chapter 11 bankruptcy protection. In a Nov. 10 release, the Phoenix-based firm says the action allows it to restructure its operations, reduce overhead and sell non-core businesses, in line with its previously discussed focus on core businesses. The filing, which does not include the firm's subsidiaries, also allows the company to access immediate liquidity through a $6.8 million line-of-credit provided by Wells Fargo, N.A. that will enable the firm to carry out day-to-day operations. The firm had to restate its financial reports for the final three quarters of 2007 and all of 2008 after an internal audit determined it improperly recorded revenues from two transactions (1"The Tan Sheet" March 2, 2009)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel